MADISON, Wis.--(BUSINESS WIRE)--TomoTherapy Incorporated (NASDAQ: TTPY), developer of the TomoTherapy® Hi·Art® treatment system for helical intensity-modulated radiation therapy (IMRT), announced today a strategic alliance with PTW, provider of advanced dosimetry and quality assurance equipment for radiation therapy. The alliance will enable TomoTherapy treatment centers worldwide to verify patient-specific treatment plans with added convenience and efficiency. “This is another important step for us,” said Peter Hoban, senior product manager for TomoTherapy Incorporated. “PTW is an innovative company, providing state-of-the-art quality assurance equipment. This alliance helps TomoTherapy add QA options and workflow enhancements to our integrated platform.”
